Personensuche
Personensuche
Es wurde 1 Person gefunden.
E-Mail
Funktionen
-
apl. Professor/in und Privatdozent/in, Klinik für Endokrinologie
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Keine vergangenen Veranstaltungen.
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Correction: Genome‑wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumorsIn: Acta Neuropathologica, Jg. 149, 2025, Nr. 1, 4DOI (Open Access)
-
Prolactin-secreting adenomas : pathogenesis, diagnosis, and managementIn: The Lancet Diabetes and Endocrinology, Jg. 13, 2025, Nr. 10, S. 874 – 890
-
Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas : A Pituitary Society international Consensus StatementIn: Nature Reviews Endocrinology, Jg. 20, 2024, Nr. 1, 62
-
Evidence for somatic mutation screening on aggressive prolactinomasIn: Nature Reviews Endocrinology, Jg. 20, 2024, Nr. 10, S. 565 – 566
-
Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumorsIn: Acta Neuropathologica, Jg. 148, 2024, Nr. 1, 68DOI, Online Volltext (Open Access)
-
Reply to ‘The shift of therapeutic strategy for prolactinomas: surgery as the first-line option’In: Nature Reviews Endocrinology, Jg. 20, 2024, Nr. 5, S. 311
-
Reply to ‘Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern’In: Nature Reviews Endocrinology, Jg. 20, 2024, Nr. 5, S. 315
-
Transition from Paediatric to Adult Care in CAH : 20 Years of Experience at a Tertiary Referral CenterIn: Hormone and Metabolic Research, Jg. 56, 2024, Nr. 1, S. 45 – 50
-
Diagnosis and management of prolactin-secreting pituitary adenomas : A Pituitary Society international Consensus StatementIn: Nature Reviews Endocrinology, Jg. 19, 2023, Nr. 12, S. 722 – 740
-
Diagnosis and management of hypertension in patients with Cushing's syndrome : a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of HypertensionIn: Journal of Hypertension, Jg. 40, 2022, Nr. 11, S. 2085 – 2101
-
Consensus on diagnosis and management of Cushing's disease : A guideline updateIn: The Lancet Diabetes and Endocrinology, Jg. 9, 2021, Nr. 12, S. 847 – 875DOI, Online Volltext (Open Access)
-
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and SwitzerlandIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 129, 2021, Nr. 3, S. 224 – 233DOI (Open Access)
-
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and AustriaIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 129, 2021, Nr. 07, S. 500 – 509DOI (Open Access)
-
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas -A German SurveyIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 105, 2020, Nr. 3, S. e660 – e675DOI (Open Access)
-
Pituitary Disease in Pregnancy : Special Aspects of Diagnosis and Treatment?In: Geburtshilfe und Frauenheilkunde, Jg. 79, 2019, Nr. 4, S. 365 – 374DOI (Open Access)
-
Aggressive pituitary tumours and carcinomas : two sides of the same coin?In: European Journal of Endocrinology (EJE), Jg. 178, 2018, Nr. 6, S. C7 – C9
-
Black swans - neuroendocrine tumors of rare locationsIn: Reviews in Endocrine and Metabolic Disorders, Jg. 19, 2018, Nr. 2, S. 111 – 121
-
Efficacy and safety of once-monthly pasireotide in Cushing's disease : a 12 month clinical trialIn: The Lancet Diabetes and Endocrinology, Jg. 6, 2018, Nr. 1, S. 17 – 26DOI, Online Volltext (Open Access)
-
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomasIn: European Journal of Endocrinology (EJE), Jg. 178, 2018, Nr. 1, S. G1 – G24DOI (Open Access)
-
MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma : PRIMARYS post-hoc analysisIn: European Journal of Endocrinology (EJE), Jg. 180, 2018, Nr. 3, S. 155 – 164DOI (Open Access)
-
Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic stepsIn: Reviews in Endocrine and Metabolic Disorders, Jg. 19, 2018, Nr. 2, S. 107 – 109DOI (Open Access)
-
Pituitary disease management during pregnancy : an overviewIn: Minerva Endocrinologica, Jg. 43, 2018, Nr. 4, S. 420 – 422
-
Secondary adrenal insufficiency in pregnancy : any differences?In: Minerva Endocrinologica, Jg. 43, 2018, Nr. 4, S. 446 – 450
-
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for molecular imaging of aldosterone-producing adenomaIn: Hypertension, Jg. 71, 2018, Nr. 2, S. 317 – 325DOI (Open Access)
-
Treatment of aggressive pituitary tumours and carcinomas : results of a European Society of Endocrinology (ESE) survey 2016In: European Journal of Endocrinology (EJE), Jg. 178, 2018, Nr. 3, S. 265 – 276
-
Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed PreventionIn: JAMA Oncology, Jg. 3, 2017, Nr. 9, S. 1204 – 1212DOI, Online Volltext (Open Access)
-
Diagnostik und Therapie der Akromegalie : Notwendigkeit der gezielten Überwachung von KomorbiditätenIn: Der Internist, Jg. 58, 2017, Nr. 11, S. 1171 – 1182
-
Erratum : Histological criteria for atypical pituitary adenomas--data from the German pituitary adenoma registry suggests modificationsIn: Acta Neuropathologica Communications, Jg. 4, 2016, S. 21
-
Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas : analysis of the German ACC registryIn: European Journal of Endocrinology (EJE), Jg. 172, 2015, Nr. 4, S. 415 – 422
-
Erratum: Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Influence of Age and Body Mass Index and Establishment of Sex-Specific Reference RangesIn: Hormone and Metabolic Research, Jg. 47, 2015, Nr. 11, S. e5
-
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modificationsIn: Acta Neuropathologica Communications, Jg. 3, 2015, S. 50DOI (Open Access)
-
How to manage pasireotide, when using as medical treatment for Cushing's diseaseIn: Endocrine, Jg. 50, 2015, Nr. 3, S. 526 – 528
-
Pituitary-directed medical therapy in Cushing's diseaseIn: Pituitary, Jg. 18, 2015, Nr. 2, S. 238 – 244
-
Qualitätssicherung der Analytik von Wachstumshormon und Insulin-Like Growth Factor I bei Erkrankungen der somatotropen AchseIn: Laboratoriumsmedizin, Jg. 39, 2015, Nr. 2, S. 81 – 86
-
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF CohortIn: Annals of Oncology, Jg. 26, 2015, Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, S. i61
-
Total testosterone and calculated estimates for free and bioavailable testosterone : Influence of age and body mass index and establishment of sex-specific reference rangesIn: Hormone and Metabolic Research, Jg. 47, 2015, Nr. 11, S. 846 – 854
-
Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine : own experience and overview of the contemporary literatureIn: Clinical Endocrinology, Jg. 82, 2015, Nr. 1, S. 84 – 90
-
Erratum to : Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension studyIn: Pituitary, Jg. 17, 2014, Nr. 2, S. 141
-
Expression Analysis of GADD45γ, MEG3, and p8 in Pituitary AdenomasIn: Hormone and Metabolic Research, Jg. 46, 2014, Nr. 9, S. 644 – 650
-
High variability in baseline urinary free cortisol values in patients with Cushing's diseaseIn: Clinical Endocrinology, Jg. 80, 2014, Nr. 2, S. 261 – 269DOI (Open Access)
-
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly : results from an open-ended, multicenter, Phase II extension studyIn: Pituitary, Jg. 17, 2014, Nr. 2, S. 132 – 140DOI (Open Access)
-
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease : results from a Phase III studyIn: Clinical Endocrinology, Jg. 81, 2014, Nr. 3, S. 408 – 417
-
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly : a randomized, multicenter, open-label, phase I studyIn: Journal of Clinical Pharmacology, Jg. 54, 2014, Nr. 11, S. 1308 – 1317
-
Sagit© : A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical PracticeIn: Value in Health, Jg. 17, 2014, Nr. 7, S. A355
-
Somatuline Autogel treatment in Acromegaly-1 year data from SOPRANo studyIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 122, 2014, Nr. 3, S. P125
-
Spontaneous course of hypophysitis - data from a survey of the German Pituitary Working GroupIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 122, 2014, Nr. 3, OP7_33
-
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly : results of a prospective multicenter clinical trialIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 99, 2014, Nr. 4, S. 1282 – 1290DOI, Online Volltext (Open Access)
-
Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general populationIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 121, 2013, Nr. 2, S. 125 – 132
-
Cardiovascular risk in patients with hypopituitarism after surgery: comparison to matched data from the general populationIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 121, 2013, S. P65
-
New avenues in the medical treatment of Cushing's disease : corticotroph tumor targeted therapyIn: Journal of Neuro-Oncology, Jg. 114, 2013, Nr. 1, S. 1 – 11DOI (Open Access)
-
Preliminary Testing of the Sagit Tool : A Tool to Help Endocrinologists in Their Management of Patients with Acromegaly in Clinical PracticeIn: Value in Health, Jg. 16, 2013, Nr. 7, S. A447DOI (Open Access)
-
Screening for Cushing's Syndrome : New Immunoassays Require Adequate Normative DataIn: Hormone and Metabolic Research, Jg. 45, 2013, Nr. 2, S. 118 – 123
-
Treatment with temozolomide in aggressive pituitary tumors - data from a survey by the German Pituitary Study GroupIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 121, 2013, Nr. 3, OP1_02
-
A 12-Month Phase 3 Study of Pasireotide in Cushing's DiseaseIn: The New England Journal of Medicine, Jg. 366, 2012, Nr. 10, S. 914 – 924
-
Automated 22-kD Growth Hormone–Specific Assay without Interference from PegvisomantIn: Clinical Chemistry, Jg. 58, 2012, Nr. 10, S. 1446 – 1456
-
Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissuesIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 120, 2012, Nr. 8, S. 482 – 489
-
Effects of standard glucocorticoid replacement therapies on subjective well-being : A randomized, double-blind, crossover study in patients with secondary adrenal insufficiencyIn: European Journal of Endocrinology (EJE), Jg. 167, 2012, Nr. 5, S. 679 – 685
-
Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomasIn: Clinical Endocrinology, Jg. 77, 2012, Nr. 1, S. 139 – 145
-
Medical management of Cushing's disease : what is the future?In: Pituitary, Jg. 15, 2012, Nr. 3, S. 330 – 341
-
Pasireotide (SOM230), a Novel Multireceptor‐Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7‐Day Subcutaneous Infusion in Healthy Male VolunteersIn: Journal of Clinical Pharmacology, Jg. 52, 2012, Nr. 7, S. 1017 – 1027
-
Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal massIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 120, 2012, Nr. 8, S. 494 – 500
-
Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency : Improved screening by an automatic immunoassayIn: European Journal of Endocrinology (EJE), Jg. 166, 2012, Nr. 4, S. 613 – 618DOI (Open Access)
-
Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers : A Single-Center, Open-Label, Ascending-Dose StudyIn: Clinical Therapeutics, Jg. 34, 2012, Nr. 3, S. 677 – 688
-
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsIn: Journal of Nuclear Medicine (JNM), Jg. 52, 2011, Nr. 12, S. 1864 – 1870
-
68Ga-DOTATOC vs. 68Ga-DOTATATE PET/CT in functional imaging of Neuroendocrine TumoursIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 38, 2011, Nr. Suppl. 2, S. 97 – S98
-
Chemotherapy in Patients with Progressive, Undifferentiated Neuroendocrine Tumors : A Single-Center ExperienceIn: Hormone and Metabolic Research, Jg. 43, 2011, Nr. 12, S. 838 – 843
-
Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LARIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 119, 2011, Nr. 3, S. 156 – 162
-
Measurement of Urinary Free Cortisol by Current Immunoassays : Need for Sex-dependent Reference Ranges to Define HypercortisolismIn: Hormone and Metabolic Research, Jg. 43, 2011, Nr. 10, S. 714 – 719
-
Monitoring medical treatment in adolescents and young adults with congenital adrenal hyperplasia : Utility of salivary 17α- hydroxyprogesterone day profilesIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 119, 2011, Nr. 3, S. 131 – 138
-
Treatment of Advanced Medullary Thyroid Carcinoma with a Combination of Cyclophosphamide, Vincristine, and Dacarbazine : a Single-Center ExperienceIn: Experimental and Clinical Endocrinology & Diabetes, Jg. 119, 2011, Nr. 9, S. 540 – 543
-
⁶⁸Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: Correlation of sst2 mRNA and SUV mₐₓIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 38, 2011, Nr. 7, S. 1224 – 1236
-
Association of somatostatin receptor 2 immunohistochemical expression with [¹¹¹In]-DTPA octreotide scintigraphy and [⁶⁸Ga]-DOTATOC PET/CT in neuroendocrine tumorsIn: Hormone and Metabolic Research, Jg. 42, 2010, Nr. 8, S. 599 – 606
-
Baseline Characteristics and Urine Free Cortisol (UFC) Variability of 162 Patients Enrolled in a Randomized, Double-Blind Phase III Study Assessing the Efficacy and Safety of Pasireotide (SOM230) in Patients with Cushings Disease
The Endocrine Society’s 92nd Annual Meeting & Expo, 1 June 2010,In: Endocrine Reviews, Jg. 31, 2010, Nr. Suppl. 1 -
Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly : Comparison with matched data from the general population and the effect of disease controlIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 95, 2010, Nr. 8, S. 3648 – 3656
-
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epitheliumIn: Hormone and Metabolic Research, Jg. 42, 2010, Nr. 1, S. 61 – 64
-
Diagnosis of adrenal insufficiency using the GHRP-6 test : Comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal diseaseIn: Hormone and Metabolic Research, Jg. 42, 2010, Nr. 3, S. 198 – 203
-
Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgeryIn: European Journal of Endocrinology (EJE), Jg. 162, 2010, Nr. 3, S. 477 – 482
-
Gibt es Hinweise auf ein Cushing-Syndrom? : Arterielle Hypertonie und AdipositasIn: MMW - Fortschritte der Medizin, Jg. 152, 2010, Nr. 7, S. 39 – 41
-
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centersIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 95, 2010, Nr. 11, S. 4925 – 4932
-
Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasmaIn: Clinical Endocrinology, Jg. 73, 2010, Nr. 2, S. 153 – 160
-
Long-Term Treatment of Acromegaly with Pasireotide (SOM230) : Results from a Phase II Extension Study
The Endocrine Society’s 92nd Annual Meeting & Expo, 1 June 2010,In: Endocrine Reviews, Jg. 31, 2010, Nr. Suppl. 1, OR 16-5 -
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly : A randomized, multicenter, phase II trialIn: The Journal of Clinical Endocrinology & Metabolism (JCEM), Jg. 95, 2010, Nr. 6, S. 2781 – 2789DOI (Open Access)
-
Posterior Retroperitoneoscopic Adrenalectomy for Clinical and Subclinical Cushing’s SyndromeIn: World Journal of Surgery, Jg. 34, 2010, Nr. 6, S. 1391 – 1397
-
Prolactinomas, Cushing's disease and acromegaly : Debating the role of medical therapy for secretory pituitary adenomasIn: BMC Endocrine Disorders, Jg. 10, 2010, S. 10DOI (Open Access)
-
Randomized, Double-Blinded, Cross-Over Study Comparing Various Glucocorticoid Substitution Schemes in Secondary Adrenal Insufficiency
The Endocrine Society’s 92nd Annual Meeting & Expo, 1 June 2010,In: Endocrine Reviews, Jg. 31, 2010, Nr. Suppl. 1 -
Recovery of pituitary function in the late-postoperative phase after pituitary surgery : Results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgeryIn: European Journal of Endocrinology (EJE), Jg. 162, 2010, Nr. 5, S. 853 – 859
-
The Effect of Pegvisomant on Cardiovascular Risk in Patients with Active Acromegaly in Comparison to Matched Data from the General Population
The Endocrine Society’s 92nd Annual Meeting & Expo, 1 June 2010,In: Endocrine Reviews, Jg. 31, 2010, Nr. 3, Suppl. 1, S. 857, OR16-6 -
The Effect of Pegvisomant on Glucose Metabolism and Insulin Levels in Healthy Adults
The Endocrine Society’s 92nd Annual Meeting & Expo, 1 June 2010,In: Endocrine Reviews, Jg. 31, 2010, Nr. Suppl. 1, S. P3 – 250 -
The rational use of pituitary stimulation testsIn: Deutsches Ärzteblatt International, Jg. 107, 2010, Nr. 25, S. 437 – 443DOI (Open Access)
-
Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epitheliumIn: Hormone and Metabolic Research, Jg. 40, 2008, Nr. 3, S. 210 – 213
-
Differential expression of ghrelin and its receptor (GHS-R1a) in various adrenal tumors and normal adrenal glandIn: Hormone and Metabolic Research, Jg. 40, 2008, Nr. 3, S. 181 – 188
-
Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumoursIn: Clinical Endocrinology, Jg. 68, 2008, Nr. 6, S. 850 – 857
-
Retroperitoneoscopic Adrenalectomy in Conn’s Syndrome Caused by Adrenal Adenomas or Nodular HyperplasiaIn: World Journal of Surgery, Jg. 32, 2008, Nr. 5, S. 847 – 853
-
Androgenproduzierender Leydig-Zell-Tumor des Ovars als Ursache von Hirsutismus bei einer postmenopausalen FrauIn: Medizinische Klinik, Jg. 102, 2007, Nr. 3, S. 259 – 262
-
Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal massIn: European Journal of Endocrinology, Jg. 154, 2006, Nr. 3, S. 409 – 417DOI (Open Access)
-
Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: Results of 161 tumors in 126 patientsIn: World Journal of Surgery, Jg. 30, 2006, Nr. 5, S. 899 – 908
-
Posterior retroperitoneoscopic adrenalectomy-results of 560 procedures in 520 patientsIn: Surgery, Jg. 140, 2006, Nr. 6, S. 943 – 950
-
Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal glandIn: Hormone and Metabolic Research, Jg. 37, 2005, Nr. 12, S. 722 – 728
-
Endoscopic treatment of large primary adrenal tumoursIn: British Journal of Surgery, Jg. 92, 2005, Nr. 6, S. 719 – 723
-
Neuroendokrine Tumoren : Seltene medizinische PhänomeneIn: Essener Unikate: Berichte aus Forschung und Lehre, 2005, Nr. 25 : Medizin – Unsere Hormone, S. 62 – 75Online Volltext, Online Volltext (Open Access)
-
Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumorsIn: Endocrine Research, Jg. 30, 2004, Nr. 4, S. 931 – 934
-
Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach : Early and long-term results of 325 consecutive procedures in primary adrenal neoplasiasIn: World Journal of Surgery, Jg. 28, 2004, Nr. 12, S. 1323 – 1329
-
Neurohormone steuern das Leben : Hormone als Vermittler zwischen Zentralnervensystem und peripheren OrganenIn: Essener Unikate: Berichte aus Forschung und Lehre, 2003, Nr. 22 : Neurowissenschaften – Wir und unser Gehirn, S. 30 – 41Online Volltext, Online Volltext (Open Access)
-
Successful transition in Congenital Adrenal Hyperplasia : A single centre experience over 20 yearsIn: Hormone Research in Paediatrics. Basel: Karger, Jg. 96, 2023, Nr. Suppl. 4, S. 147 – 148
-
Association of Somatostatin Receptor 2 Immunohistochemical Expression with [111In]-DTPA Octreotide Scintigraphy and [68Ga]-DOTATOC PET/CT in Neuroendocrine Tumors
7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease March 11–12, 2010 Berlin, Germany,In: Neuroendocrinology. Basel: Karger, Jg. 92, 2010, Nr. 1, S. 47 -
Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas : A Single-Center Experience
7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease March 11–12, 2010 Berlin, Germany,In: Neuroendocrinology. Basel: Karger, Jg. 92, 2010, Nr. 1, S. 27 -
Differential Uptake of 68Ga-DOTATOC and 68Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine TumorsIn: Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment / Baum, Richard P.; Rösch, Frank (Hrsg.). Heidelberg: Springer, 2013, S. 353 – 371